Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy Academic Article Article uri icon

Overview

MeSH Major

  • Bronchi
  • Carcinoma, Non-Small-Cell Lung
  • Epithelial Cells
  • Gene Expression Regulation, Neoplastic
  • Lung Neoplasms
  • NF-kappa B

abstract

  • Seventy-two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty-three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.

publication date

  • January 1984

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(1984)54:4<744::AID-CNCR2820540426>3.0.CO;2-P

PubMed ID

  • 6378356

Additional Document Info

start page

  • 744

end page

  • 50

volume

  • 54

number

  • 4